Showing results (2601-2610 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|February 9, 2022
Orelabrutinib-bruton tyrosine kinase inhibitor-based regimens in the treatment of central nervous system lymphoma: a retrospective studyJing-Jing Wu, Wen-Hua Wang, Meng Dong, et al.
Investigational New Drugs|January 28, 2022
Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cellsLu Wang, Dan Hu, Bin Xie, et al.
Investigational New Drugs|April 28, 2022
Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experienceWen-Chi Wu, Tzu-Yuan Lin, Ming-Huang Chen, et al.
Investigational New Drugs|April 28, 2022
NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cellsJean Carlos Lipreri da Silva, Maria Fernanda Lopes Carvalho, Livia Bassani Lins de Miranda, et al.
Investigational New Drugs|March 21, 2022
The addition of the immunomodulator mifamurtide to adjuvant chemotherapy for early osteosarcoma: a retrospective analysisStefania Kokkali, Ioannis Kotsantis, Elpida Magou, et al.
Investigational New Drugs|March 21, 2022
Poly-guanidine shows high cytotoxicity in glioma cell cultures and glioma stem cellsMarcela Márquez, Karl Holmberg Olausson, Ayodele Alaiya, et al.
Investigational New Drugs|March 30, 2022
Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapyShahd M Hassona, Entsar A Saad, Hala A Kiwan, et al.
Investigational New Drugs|April 11, 2022
A small molecule inhibitor of VSIG-8 prevents its binding to VISTAWenting Chen, Chenxin Qie, Xinlei Hu, et al.
Investigational New Drugs|September 1, 2018
Preclinical assessment of histone deacetylase inhibitor quisinostat as a therapeutic agent against esophageal squamous cell carcinomaLei Zhong, Shu Zhou, Rongsheng Tong, et al.
Investigational New Drugs|September 11, 2018
Phase I/II study of first-line combination therapy with sorafenib plus resminostat, an oral HDAC inhibitor, versus sorafenib monotherapy for advanced hepatocellular carcinoma in east Asian patientsWon Young Tak, Baek-Yeol Ryoo, Ho Yeong Lim, et al.
Pageof 372